Agape ATP (NASDAQ:ATPC) Trading Down 5.3% - Time to Sell?

Key Points

• Agape ATP's stock price dropped 5.3% during mid-day trading, reaching a low of $1.15 before closing at $1.17, with a significant decline in trading volume.
• The company holds a market capitalization of $58.26 million and has a negative PE ratio of -2.84, reflecting poor financial performance.
• Weiss Ratings has given Agape ATP a "sell (e+)" rating, indicating analyst sentiments that suggest caution for potential investors.

Agape ATP Corporation (NASDAQ:ATPC - Get Free Report)'s stock price fell 5.3% during mid-day trading on Tuesday . The stock traded as low as $1.15 and last traded at $1.17. 6,846 shares were traded during mid-day trading, a decline of 74% from the average session volume of 26,249 shares. The stock had previously closed at $1.23.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Agape ATP in a research report on Saturday, September 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of "Sell".

Agape ATP Stock Performance

The company has a market capitalization of $58.26 million, a PE ratio of -2.84 and a beta of -0.95. The company has a 50 day moving average price of $1.30 and a 200 day moving average price of $1.50.

Agape ATP (NASDAQ:ATPC - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.01) EPS for the quarter. Agape ATP had a negative net margin of 183.13% and a negative return on equity of 20.32%.

About Agape ATP

Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.